A 70-year-old man diagnosed with idiopathic pulmonary fibrosis (IPF) one year earlier developed progressive exertional dyspnea 3 weeks after onset of coronavirus disease 2019 (COVID-19). High-resolution computed tomography showed new extensive ground-glass opacities with rapidly progressive honeycombing. Although he was diagnosed with acute exacerbation (AE) of IPF triggered by COVID-19 and received methylprednisolone pulse therapy twice within one month, there was no improvement of oxygenation and lung involvement. Three months after COVID-19 onset, it was decided to provide best supportive care. An AE of IPF as a sequela of COVID-19, which is recognized as macrophage activation syndrome, is fatal, and in this case, the measurement of serum heme oxygenase-1, which is a macrophage activation biomarker involved in pulmonary cellular protection against oxidative stress, was useful for tracking disease activity.
【저자키워드】 Macrophage, Coronavirus disease 2019, Biomarker, Heme oxygenase-1, Lung injury burst, 【초록키워드】 COVID-19, Methylprednisolone, coronavirus disease, therapy, lung involvement, pulmonary fibrosis, oxidative stress, Computed tomography, ground-glass opacity, serum, Dyspnea, macrophage activation syndrome, macrophage activation, IPF, Disease activity, cellular, supportive care, Oxygenation, acute exacerbation, pulse, involved, diagnosed, triggered, 【제목키워드】 coronavirus disease, pulmonary fibrosis, serum, clinical, Patient, acute exacerbation, triggered,